09.01.2018 14:30:00
|
Nolopecia, a Revolutionary Herbal Treatment for Hair Loss and Balding, Introduced by Lilac Corp
SARASOTA, Fla., Jan. 9, 2018 /PRNewswire/ -- Lilac Corp is happy to announce the launch of Nolopecia, a new herbal treatment for hair loss and balding. Lilac Corp is the company that sells the highly acclaimed Gene-Eden-VIR and Novirin.
Dr. Hanan Polansky and his team from the Center for the Biology of Chronic Disease discovered that latent viruses increase the production of the two proteins associated with the development of hair loss and balding in both men and women, dihydrotestosterone (DHT) and the androgen receptor (AR). Following this discovery, Lilac Corp developed Nolopecia, a natural treatment that targets the latent viruses that modify the levels of DHT and AR. Controlling the number of latent viruses helps maintain normal levels of these two proteins, resulting in normal hair growth.
About Nolopecia
Nolopecia comes in a form of a capsule taken twice a day orally. This product is unique. It is the only product on the market that targets latent viruses, which according to Dr. Hanan Polansky, cause most cases of hair loss and balding (androgenic alopecia). Lilac Corp is pleased to invite interested individuals to try this revolutionary product. Nolopecia can be ordered on the product website at http://nolopecia.com/
Media contact:
John Roberts
Lilac Corp
585-250-9999
View original content with multimedia:http://www.prnewswire.com/news-releases/nolopecia-a-revolutionary-herbal-treatment-for-hair-loss-and-balding-introduced-by-lilac-corp-300579270.html
SOURCE Lilac Corp
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Albemarle Corp.mehr Nachrichten
30.12.24 |
S&P 500-Wert Albemarle-Aktie: So viel hätte eine Investition in Albemarle von vor 5 Jahren abgeworfen (finanzen.at) | |
27.12.24 |
Angespannte Stimmung in New York: S&P 500 gibt zum Start des Freitagshandels nach (finanzen.at) | |
23.12.24 |
S&P 500-Wert Albemarle-Aktie: So viel Verlust hätte ein Albemarle-Investment von vor 3 Jahren eingefahren (finanzen.at) | |
18.12.24 |
Verluste in New York: S&P 500 zum Ende des Mittwochshandels in der Verlustzone (finanzen.at) | |
16.12.24 |
S&P 500-Titel Albemarle-Aktie: So viel Verlust hätte ein Albemarle-Investment von vor einem Jahr eingebracht (finanzen.at) | |
13.12.24 |
Schwacher Handel in New York: S&P 500 notiert am Freitagnachmittag im Minus (finanzen.at) | |
10.12.24 |
Anleger in New York halten sich zurück: S&P 500 sackt schlussendlich ab (finanzen.at) | |
10.12.24 |
NYSE-Handel: S&P 500 am Mittag freundlich (finanzen.at) |
Analysen zu Albemarle Corp.mehr Analysen
Aktien in diesem Artikel
Albemarle Corp. | 85,21 | 2,75% |